Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Biocon Pebrilzo Launch: Big Win Clears 2027 EU Path
Biocon Pebrilzo launch: a Genentech settlement allows EU and UK sales in Q1 2027 and US in Q3 2028, subject to approvals. Dates, status and what is undisclosed.
Argatroban Injection Recall 2026: Urgent Alert for 22 Lots
Argatroban injection recall 2026: Par Health recalls 22 lots over particulate matter. See the lot numbers, risks, hospital instructions and contacts.
Anktiva FDA Approval: Powerful New Option for Bladder Cancer
Anktiva FDA approval now covers BCG-unresponsive bladder cancer with papillary-only tumours as well as CIS. See the data, dosing, safety warnings and caveats.
Viking Therapeutics VK2735 Phase 3 Trial: Bold Oral Gamble
Viking Therapeutics VK2735 Phase 3 trial: two 68-week SUNRISE studies of oral VK2735 will enrol about 560 adults each. The drug is still investigational.
Kerala Elderly Care Bill 2026: Bold Move to Protect Seniors
Kerala elderly care bill 2026 would register care homes, certify caregivers and set jail terms of up to three years for abuse. It is not yet law. Details.
Congo Ebola Outbreak October 2026: Alarming Rise Past 9,000
Congo Ebola outbreak October 2026: government figures show 9,066 confirmed cases and 4,381 deaths. See WHO data, spread, risks and what to watch next.
BMF-650 Phase 1 Clinical Trial Results: Critical Early Data
BMF-650 Phase 1 clinical trial results: 1.5% to 3.2% weight loss in outpatient cohorts; a 6.1% cohort had similar placebo loss. Early, unapproved.
Zealand Pharma Generate Biomedicines Deal: Powerful AI Pact
Zealand Pharma Generate Biomedicines deal: $30M upfront and up to nearly $1.2B in potential milestones for AI-designed obesity drugs. Nothing is guaranteed.
NMC Digital Signature Guidelines 2026: Essential Safeguards
NMC digital signature guidelines 2026: doctors may remotely authenticate records after personal review, with audit trails. The advisory clarifies existing law.
NVIDIA Doctolib Investment: Bold Bet on Clinical AI
NVIDIA Doctolib investment: a planned minority stake to speed AI tools for clinicians. The amount is undisclosed and no patient-outcome data were reported.